TY - JOUR
T1 - Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles
T2 - A prospective randomized controlled trial
AU - Amir, Hadar
AU - Yaniv, Dan
AU - Hasson, Joseph
AU - Amit, Ami
AU - Gordon, David
AU - Azem, Foad
N1 - Publisher Copyright:
© Journal of Reproductive Medicine®, Inc.
PY - 2015/2
Y1 - 2015/2
N2 - Objective: To investigate whether cabergoline (Cb2), a dopamine agonist, reduces ovarian hyperstimulation syndrome (OHSS) in high-risk women undergoing assisted reproductive technology (ART), and to analyze whether cabergoline affects the outcome of ART. Study Design: Forty infertile women at risk of developing OHSS were enrolled in the trial. The inclusion criteria were as follows: infertile women undergoing IVF with serum estradiol concentration > 4,000 pg/mL or with > 20 follicles > 12 mm on the day of human chorionic gonadotropin (hCG) administration, and 18–40 years of age. They were randomized into 2 groups: the Cb2 group (n=20) received 0.5 mg oral Cb2 per day for 8 consecutive days beginning on the day of hCG, and the control group (n=20) received no medication. Results: Ascites was significantly lower (p=0.008) in the Cb2 group as compared with the control group. The incidence of moderate OHSS was also significantly lower (p=0.04) in the Cb2 as compared to the control group. There was no evidence of statistically significant differences regarding the parameters of ART outcome. Conclusion: Our data supports the use of Cb2 in the management of high-risk women undergoing ART and, consequently, achieving lowered risk of OHSS, with no deleterious impact on ART outcomes.
AB - Objective: To investigate whether cabergoline (Cb2), a dopamine agonist, reduces ovarian hyperstimulation syndrome (OHSS) in high-risk women undergoing assisted reproductive technology (ART), and to analyze whether cabergoline affects the outcome of ART. Study Design: Forty infertile women at risk of developing OHSS were enrolled in the trial. The inclusion criteria were as follows: infertile women undergoing IVF with serum estradiol concentration > 4,000 pg/mL or with > 20 follicles > 12 mm on the day of human chorionic gonadotropin (hCG) administration, and 18–40 years of age. They were randomized into 2 groups: the Cb2 group (n=20) received 0.5 mg oral Cb2 per day for 8 consecutive days beginning on the day of hCG, and the control group (n=20) received no medication. Results: Ascites was significantly lower (p=0.008) in the Cb2 group as compared with the control group. The incidence of moderate OHSS was also significantly lower (p=0.04) in the Cb2 as compared to the control group. There was no evidence of statistically significant differences regarding the parameters of ART outcome. Conclusion: Our data supports the use of Cb2 in the management of high-risk women undergoing ART and, consequently, achieving lowered risk of OHSS, with no deleterious impact on ART outcomes.
KW - Assisted
KW - Assisted reproductive techniques
KW - Cabergoline
KW - Dopamine agonist
KW - Ovarian hyperstimulation syndrome
KW - Reproductive technology
KW - Vascular endothelial growth factor receptor–2 (VEGFR-2)
UR - http://www.scopus.com/inward/record.url?scp=84949810310&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:84949810310
SN - 0024-7758
VL - 60
SP - 48
EP - 54
JO - Journal of Reproductive Medicine
JF - Journal of Reproductive Medicine
IS - 1
ER -